source
- Sofinnova Partners raises €725M crossover fund to back later-stage European biotech firmsSofinnova Partners, a leading European life‑science venture firm, announced that it has closed a second crossover fund worth 725 million euros (about $815 million). The new vehicle, called Sofinnov…
- FDA rejects Summit and Akeso's ivonescimab for narrow lung cancerThe U.S. Food and Drug Administration has turned down ivonescimab, a new cancer therapy being developed by Summit Therapeutics and Akeso, for use in a specific type of lung cancer. Analysts had la…